Commentary: targeting myelodysplastic syndromes.
Division of Medical Oncology, Duke University Medical Center, Box 3872, Durham, NC 27710, USA .
Carlos M
CM
de Castro
D000970:Antineoplastic Agents; D016207:Cytokines / Q000037:antagonists & inhibitors; D015195:Drug Design; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000209:etiology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000970:Antineoplastic Agents; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha